Read what we’re doing to ensure PCCA Formulas for compounding sterile preparations comply with USP Chapter 797 revisions.

From its humble origins as a textile dye, methylene blue has transformed into a versatile clinical agent with a wide range of potential applications.

Get flavoring tips for masking two bitter active pharmaceutical ingredients (APIs) from our flavoring expert.

Learn about the properties — including a biomarker for efficacy, known and unknown mechanisms of action and more — of minoxidil, the only FDA approved topical active pharmaceutical ingredient (API) for alopecia in men and women.

We’ve expanded our Lipoderm family of permeation-enhancing bases and offer helpful tips, including which Lipoderm base works best for specific APIs, when compounding preparations for your patients.

Read more about how Canada and the U.S. regulators approach drug shortages, including duplicating approved drugs and the impacts of last winter’s drug shortages.

North America’s two largest countries, Canada and the U.S., have very different approaches to drug shortages. Read Part 1 of our two-part series to learn more about the distinctions between Health Canada and FDA regulations.

As we wind down National Arthritis Awareness Month, learn how compounders may help patients with the most common type of arthritis using compounded preparations and nutritional supplements.

Polycystic ovary syndrome (PCOS) is the most prevalent hormonal disorder affecting women of reproductive age across the globe and the CDC estimates PCOS may be one of the most common causes of infertility. Learn how to help patients with PCOS.

Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.